CYP26A1 and neoplasm: The anti-proliferative effects of CYP26A1 inhibitors Liarozole and Talarozole were evaluated alone and in combination with Sulindac and Piroxicam, which have anti-tumor activity against APC-mutant tissues (Figure 6 and Figure S3).